BioXcel Secures $1.25M Lifeline Loan, Liquidity Covenant Slashed to $250K
BTAI is trading near its 52-week low of $0.737 (6.1% above the low).
Summary
BioXcel borrowed another $1.25M from Oaktree at a 20% upfront fee, had its minimum liquidity requirement cut to $250K, and now faces an August 31 deadline to close a lender-approved transaction.
Key Events · Financing and Capital Events · BTAI
-
New $1.25M Term Loan at 20% Upfront Fee
Lenders provided an additional $1,250,000 loan under the Fourteenth Amendment, with BioXcel paying a $250,000 upfront fee (20% of principal).
-
Minimum Liquidity Covenant Slashed to $250K
The required minimum cash liquidity was reduced from $3.0 million to $250,000, reflecting the company's depleted cash position.
-
August 31 Transaction Deadline
BioXcel must enter into definitive agreements for a lender-acceptable transaction by August 31, 2026 — extended from August 28 — or face default.
-
Operational Flexibility Removed
Covenants were amended to remove flexibility for out-licensing intellectual property and selling assets, tightening lender control over strategic options.
Analysis · BTAI · Life Sciences
BioXcel Therapeutics entered into its Fourteenth Amendment to its credit agreement with Oaktree, borrowing an additional $1.25 million at a punishing 20% upfront fee. The lenders simultaneously cut the minimum liquidity covenant from $3.0 million to just $250,000 — a concession that keeps the company technically compliant but signals how close it is to insolvency. The company must now finalize a transaction acceptable to lenders by August 31, 2026, just six days away, or face default. This is the fourth debt-related amendment in under two months, each one tightening lender control and stripping away operational flexibility, including new restrictions on out-licensing intellectual property and asset sales.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTAI was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8M. The 52-week trading range was $0.74 to $5.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.